What is ARA-290?
ARA-290 (cibinetide) is an investigational EPO-derived peptide with limited, supervised human research in selected neuropathy populations. Both listed research suppliers sell a 10 mg vial, which is not a licensed medicine.
Research classification: Research summary · not a validated human regimen. The ARA-290 10 mg vial label reports nominal content; it does not state a suitable amount for human use.
Mechanism and research questions
Investigational tissue-protection signalling investigated in preclinical and small human studies; clinical benefit has not been established for these vials.
Mechanistic findings and early experiments do not by themselves establish clinical efficacy, an approved treatment cycle or equivalence between suppliers' formulations. Interpret claims in the context of the specific experimental model and references.
How to read a reported schedule
The earlier catalogue entry described research examples, not a clinically validated schedule for people. The dose, route, frequency or escalation used in one experiment cannot be generalised to a different formulation or to an individual. When primary evidence is not available, do not treat a catalogue number as a recommendation.
For the existing schedule, its evidence caveats and the concentration calculator, see the ARA-290 protocol and vial reference. Figures displayed there are research context, not a personalised prescription.
Vial identity and preparation
An exact-matching Peak Peptides Australia 10 mg vial is shown on the research reference page. The product is supplied for in-vitro research, not administration.
Reconstitution cannot be inferred from vial strength alone. Confirm the exact compound, lot, expected appearance, compatible sterile diluent, final volume, transfer method and discard/storage period from validated formulation documentation. BAC water and a 28-day period are not universal defaults. See the illustrated product-specific preparation guide and the abnormal-solution safety guide.
View Peak Peptides Australia's research-only listing and confirm its current labelled strength.
Sources, limits and next steps
No independently reviewed primary human protocol has been attached to this catalogue article. A cited bibliography should be obtained before interpreting any reported schedule.
For clinical decisions, consult a qualified professional and the product information for an approved formulation. Research-only supplier material must not be injected or used to treat a condition. Explore the A–Z research directory to compare evidence categories.